AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17229788 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent use of a supervised safer injection facility (SIF)
Number of subjects: 760
Study 17229788 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent use of a supervised safer injection facility (SIF)
Number of subjects: 760
Study 15346305 — intervention group
Group type: EXPERIMENTAL
Intervention: NASS outcome instrument
Number of subjects: 70
Study 15346305 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 70
Study 15346305 — intervention group
Group type: EXPERIMENTAL
Intervention: FFbH-R
Number of subjects: 70
Study 11665351 — intervention group
Group type: EXPERIMENTAL
Intervention: One Drop Only Tongue Cleaner
Number of subjects: 30
Study 11665351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue Scraper
Number of subjects: 30
Study 11665351 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 30
Study 9843009 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% retinaldehyde cream
Number of subjects: 125
Study 9843009 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% retinoic acid cream
Number of subjects: 125
Study 9843009 — intervention group
Group type: COMPARATOR
Intervention: Retinaldehyde vehicle
Number of subjects: 125
Study 7978141 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia regimen using morphine 1 mg.ml‐1 solution
Number of subjects: 50
Study 7978141 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia regimen using morphine 1 mg.ml‐1 with metoclopramide 0.5 mg.ml‐1 solution
Number of subjects: 50
Study 2609898 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol-Biogram formulation (1% dithranol applied for 20 min after UV-B treatment)
Number of subjects: 33
Study 2609898 — intervention group
Group type: COMPARATOR
Intervention: Conventional ex-tempore formulation (1% dithranol applied for 20 min after UV-B treatment)
Number of subjects: 33
Study 30477834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic Acid (LA) 1200 mg daily for 2 years
Number of subjects: 21
Study 30477834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic Acid (LA)
Number of subjects: 21
Study 30477834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 21
Study 28494765 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc lozenges
Number of subjects: 2
Study 28494765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 26132079 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (3 daily fish-oil capsules, each containing 280 mg DHA, 90 mg EPA and 2 mg Vitamin E)
Number of subjects: 250
Study 26132079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 24256677 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP)
Number of subjects: 96
Study 24256677 — intervention group
Group type: COMPARATOR
Intervention: Catecholamines (CAs)
Number of subjects: 96
Study 21910067 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiongshao Capsule (XS)
Number of subjects: 335
Study 21910067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 18373281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning plus tourniquet (IP-T group)
Number of subjects: 20
Study 18373281 — intervention group
Group type: COMPARATOR
Intervention: Control group with only tourniquet application (T group)
Number of subjects: 20
Study 16533676 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially produced information booklets (3 booklets provided at pre-assessment, before surgery, and at discharge)
Number of subjects: 109
Study 16533676 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital information only
Number of subjects: 109
Study 12715913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue and oral mucosa cleaning (oral care) after lunch every day or every other day for two consecutive weeks
Number of subjects: 84
Study 11061760 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment (Curosurf, Survanta, Alveofact, Exosurf)
Number of subjects: 118
Study 11061760 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment
Number of subjects: 118
Study 11061760 — intervention group
Group type: COMPARATOR
Intervention: Control group (noninfected infants with RDS)
Number of subjects: 118
Study 8973026 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week educational intervention on ADHD
Number of subjects: 20
Study 8973026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 1534664 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 12
Study 4054319 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 49
Study 4054319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 30842257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 32
Study 30842257 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 32
Study 30842257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 32
Study 28147899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued recall condition
Number of subjects: 0
Study 28147899 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated practice condition
Number of subjects: 0
Study 28147899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27339848 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally delivered focused ultrasound for renal denervation
Number of subjects: 69
Study 24656142 — intervention group
Group type: EXPERIMENTAL
Intervention: MLVA (multilocus variable repeat analysis)
Number of subjects: 11
Study 24656142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribotyping
Number of subjects: 11
Study 24656142 — intervention group
Group type: EXPERIMENTAL
Intervention: Typing tests
Number of subjects: 11
Study 24656142 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory turnaround time < 3 days
Number of subjects: 11
Study 24656142 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational factors
Number of subjects: 11
Study 24656142 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved discrimination provided by MLVA typing
Number of subjects: 11
Study 22721353 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 73
Study 22721353 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 20089269 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin twice a day for 4 weeks
Number of subjects: 200
Study 20089269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 18448709 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy for a 65-year-old patient
Number of subjects: 0
Study 18448709 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy for a 25-year-old patient (physician role)
Number of subjects: 0
Study 18448709 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy for a 25-year-old patient (abstract other role)
Number of subjects: 0
Study 18448709 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive chemotherapy for a 25-year-old patient (self role)
Number of subjects: 0
Study 16125527 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone plus testosterone (GH plus T) administration
Number of subjects: 103
Study 16125527 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 103
Study 16125527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex steroid administration (hormone replacement therapy in women, testosterone enanthate in men)
Number of subjects: 103
Study 16125527 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone administration
Number of subjects: 103
Study 11870507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with radioimmunotherapy in glioblastoma patients
Number of subjects: 37
Study 11870507 — intervention group
Group type: COMPARATOR
Intervention: Control group (glioblastoma patients)
Number of subjects: 37
Study 11870507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with radioimmunotherapy in grade III glioma patients
Number of subjects: 37
Study 10701474 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-225 mg/day (n = 100)
Number of subjects: 301
Study 10701474 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20-60 mg/day (n = 103)
Number of subjects: 301
Study 10701474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 98)
Number of subjects: 301
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (CLB)
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide (PGB)
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OCBZ)
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (FNR)
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Milacemide (MLM)
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐801
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS)
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezinamide
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Loreclezole
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafimidone
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG‐6370
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ralitoline
Number of subjects: 21
Study 8784219 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiripentol
Number of subjects: 21
Study 2110703 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b polysaccharide‐protein conjugate vaccine (PRP‐D) mixed with meningococcal and/or pneumococcal capsular polysaccharide vaccines
Number of subjects: 293
Study 2110703 — intervention group
Group type: EXPERIMENTAL
Intervention: Halved vaccine dose
Number of subjects: 293
Study 2110703 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple vaccine antigens
Number of subjects: 293
Study 760017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine (1 g preoperatively followed by 500 mg IV q. 6 hours for 4 doses)
Number of subjects: 0
Study 760017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine (2 g IV given approximately 1 hour before surgery)
Number of subjects: 0
Study 760017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30973790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg/d
Number of subjects: 500
Study 29354916 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast acupuncture
Number of subjects: 60
Study 29354916 — intervention group
Group type: COMPARATOR
Intervention: Retaining needle
Number of subjects: 60
Study 26514220 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous local analgesic infusion (ScLAI) with bupivacaine
Number of subjects: 15
Study 26514220 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 15
Study 23897696 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expectancy-related warning labels
Number of subjects: 40
Study 23897696 — intervention group
Group type: COMPARATOR
Intervention: Health-related warning labels
Number of subjects: 40
Study 20962656 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS on bilateral ST36 and SP6 acupoints, continuous mode at 15 Hz, intensity of 10 mA for 30 min
Number of subjects: 52
Study 20962656 — intervention group
Group type: COMPARATOR
Intervention: Non-stimulation (placebo group)
Number of subjects: 52
Study 18488437 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with tiotropium
Number of subjects: 61
Study 18488437 — intervention group
Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 61
Study 17489939 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline infusion
Number of subjects: 25
Study 12619267 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/sodium fluoride toothpaste
Number of subjects: 0
Study 12619267 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride toothpaste
Number of subjects: 0
Study 12619267 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (no fluoride)
Number of subjects: 0
Study 10867779 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE*E4 carriers in Indian sample (aged 70 years or older)
Number of subjects: 5336
Study 10867779 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE*E4 carriers in US sample (aged 70 years or older)
Number of subjects: 5336
Study 10867779 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of APOE*E4 in Indian sample (aged 70 years or older)
Number of subjects: 5336
Study 10867779 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers of APOE*E4 in US sample (aged 70 years or older)
Number of subjects: 5336
Study 9214247 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 715
Study 9214247 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of stenosis to 80% or more
Number of subjects: 715
Study 9214247 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated ultrasonography
Number of subjects: 715
Study 1403593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline fibers
Number of subjects: 10
Study 1403593 — intervention group
Group type: COMPARATOR
Intervention: Placebo fibers
Number of subjects: 10
Study 3893006 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ST)
Number of subjects: 107
Study 3893006 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 107
Study 30191302 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective replacement of PIVC (every 72-96 hours)
Number of subjects: 113
Study 30191302 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (replacement when clinically indicated)
Number of subjects: 113
Study 30191302 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective replacement of PIVC
Number of subjects: 113
Study 30191302 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 113
Study 27105583 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation training
Number of subjects: 72
Study 27105583 — intervention group
Group type: COMPARATOR
Intervention: Nutrition information training
Number of subjects: 72
Study 25468986 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention group (access to point‐of‐care tests, prescriber feedback, courses for GPs, guidelines, patient information leaflets, workshops)
Number of subjects: 25479
Study 25468986 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention group (all interventions except workshop and access to point‐of‐care tests)
Number of subjects: 25479
Study 25468986 — intervention group
Group type: COMPARATOR
Intervention: Subjects requesting antibiotics (overall comparison)
Number of subjects: 25479
Study 22512291 — intervention group
Group type: EXPERIMENTAL
Intervention: OBI-1
Number of subjects: 9
Study 22512291 — intervention group
Group type: COMPARATOR
Intervention: Hyate:C
Number of subjects: 9
Study 22512291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20158291 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg/70 kg, oral)
Number of subjects: 80
Study 20158291 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg, oral)
Number of subjects: 80
Study 20158291 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.25 mg/70 kg, subcutaneous)
Number of subjects: 80
Study 20158291 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.50 mg/70 kg, subcutaneous)
Number of subjects: 80
Study 20158291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18190986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stent (SES) implantation, n=65
Number of subjects: 129
Study 18190986 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary brachytherapy (ICBT), n=64
Number of subjects: 129
Study 15765440 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly experienced interpreters (N = 3)
Number of subjects: 72
Study 15765440 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately experienced interpreters (N = 3)
Number of subjects: 72
Study 15765440 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced interpreters (N = 2)
Number of subjects: 72
Study 15765440 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement for achalasia diagnosis
Number of subjects: 72
Study 15765440 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement for normal motility diagnosis
Number of subjects: 72
Study 15765440 — intervention group
Group type: EXPERIMENTAL
Intervention: Other manometric diagnoses (DES, IEM, hypo- and hypertensive LES)
Number of subjects: 72
Study 15765440 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 72
Study 12422622 — intervention group
Group type: EXPERIMENTAL
Intervention: Aronia in combination with apple pectin (15 g of apple pectin and 20 ml of Aronia concentrate twice daily)
Number of subjects: 42
Study 12422622 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 age-matched women with breast cancer)
Number of subjects: 42
Study 10482930 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim-mobilized PBPC (n = 15)
Number of subjects: 44
Study 10482930 — intervention group
Group type: COMPARATOR
Intervention: Unstimulated BM (n = 14)
Number of subjects: 44
Study 10482930 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPC (n = 15, non-randomized)
Number of subjects: 44
Study 8621799 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO therapy
Number of subjects: 8
Study 8621799 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control subjects
Number of subjects: 8
Study 1677212 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threonine, dosage and duration not specified
Number of subjects: 0
Study 7037662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin (350 mg, three times daily for 15 days)
Number of subjects: 52
Study 7037662 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin (250 mg, three times daily for 15 days)
Number of subjects: 52
Study 7037662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 52
Study 30845690 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional olive oil (FOO, 487 ppm of phenolic compounds and enriched with 389 ppm of triterpenes)
Number of subjects: 51
Study 30845690 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional olive oil (FOO)
Number of subjects: 51
Study 27841790 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray (saline spray)
Number of subjects: 40
Study 27841790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid spray (phosphatidylcholine; Tears again)
Number of subjects: 40
Study 27841790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid drop (phosphatidylglycerine; Systane Balance)
Number of subjects: 40
Study 27841790 — intervention group
Group type: COMPARATOR
Intervention: Placebo drop (saline drop)
Number of subjects: 40
Study 27841790 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic wearers with spray treatment
Number of subjects: 40
Study 27841790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid drop
Number of subjects: 40
Study 27841790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular comfort
Number of subjects: 40
Study 26825840 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with or without radiation therapy (RT) (intravaginal or pelvic)
Number of subjects: 85
Study 26825840 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (intravaginal RT or pelvic RT) alone
Number of subjects: 85
Study 26825840 — intervention group
Group type: EXPERIMENTAL
Intervention: No adjuvant treatment
Number of subjects: 85
Study 26825840 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 85
Study 26825840 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis
Number of subjects: 85
Study 25224104 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0
Study 25224104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22081241 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Number of subjects: 204
Study 19940281 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 239
Study 19940281 — intervention group
Group type: COMPARATOR
Intervention: No systemic treatment
Number of subjects: 239
Study 17588243 — intervention group
Group type: EXPERIMENTAL
Intervention: Funhaler (FH)
Number of subjects: 47
Study 17588243 — intervention group
Group type: COMPARATOR
Intervention: Control small volume spacer
Number of subjects: 47
Study 15175057 — intervention group
Group type: EXPERIMENTAL
Intervention: Left superior pulmonary vein (LSPV) isolation followed by additional isolation of the right superior pulmonary vein (RSPV) in case of AF recurrence (group A, n = 27)
Number of subjects: 52
Study 15175057 — intervention group
Group type: COMPARATOR
Intervention: Isolation of all four pulmonary veins (group B, n = 25)
Number of subjects: 52
Study 15175057 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (LSPV isolation)
Number of subjects: 52
Study 15175057 — intervention group
Group type: COMPARATOR
Intervention: Group B (isolation of all four PVs)
Number of subjects: 52
Study 11600257 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyphecan (1‐4,2‐acetamide‐deoxy‐B‐D‐glucan)
Number of subjects: 35
Study 11600257 — intervention group
Group type: COMPARATOR
Intervention: Kaltostat (calcium sodium alginate)
Number of subjects: 35